1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Shenzhen Chipscreen Biosciences Co. Ltd. Class A

Shenzhen Chipscreen Biosciences Co. Ltd. Class A

SSSE:688321
22.18
CNY
-0.41
(-1.81%)
0.24EPS
110.35P/E
11.66BMarket Cap
Oct 28Next Earn
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.26
0.32
0.41
0.46
0.66
1.05
1.3
1.28
1.61
2.23
2.43
Basic EPS, GAAP
0.02
0.07
0.09
0.05
0.08
0.05
0.04
0.22
-0.28
0.13
0.24
Free Cash Flow per Basic Share
-0.02
-0.37
-0.33
-0.42
-0.59
-0.4
-0.88
-0.95
-0.47
-0.2
- -
Dividend per Share
0.01
0.01
- -
- -
0.01
0.01
0.03
0.05
0.07
0.08
0.12
Book Value per Share
0.59
1.25
1.32
3.53
3.64
3.45
3.69
4.16
3.88
3.99
5.76
Tangible Book Value per Share
0.36
0.85
0.82
3.03
3
2.58
2.55
2.74
2.4
2.37
4.19
Basic Weighted Avg Shares
330
349
360
376
410
409
407
408
408
408
420
Sales/Revenue/Turnover
85
111
148
174
269
430
530
524
658
910
1,023
Operating Margin (%)
1.77
24.65
19.32
6.54
7.29
3.59
3.26
-31.43
-8.39
10.95
15.22
Depreciation Expense
4
4
4
5
11
20
39
44
59
70
- -
Net Income, GAAP
5
24
31
19
31
22
17
89
-115
51
100
Effective Tax Rate (%)
- -
- -
3.11
6.33
14.16
- -
15.44
49.3
- -
- -
- -
Profit Margin (%)
6.14
21.79
21.1
11.17
11.52
5.1
3.3
16.96
-17.41
5.6
9.8
Working Capital
114
234
152
935
617
345
644
739
632
336
1,127
LT Debt
30
65
88
37
25
6
599
909
1,096
1,040
1,094
Total Equity
213
451
477
1,446
1,494
1,418
1,576
1,710
1,581
1,626
2,550
Return on Invested Capital (%)
- -
- -
5.71
1.9
2.03
- -
0.68
1.89
- -
- -
- -
Return on Capital (%)
- -
- -
5.76
1.96
2.05
- -
1.98
5.65
- -
- -
- -
Return on Common Equity (%)
- -
7.25
6.72
2.02
2.11
1.51
1.19
5.51
-6.96
3.18
4.88

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
507
491
414
LT Borrowings
1,035
1,048
1,090
LT Finance Leases
5
4
4
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
408
443
443
Market Capitalization
11,916
12,655
11,663

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,180
2,064
1,944
Cash, Cash Equivalents & STI
643
1,514
1,379
Accounts Receivable, Net
287
295
311
Inventories
58
58
66
Total Current Liabilities
844
805
817
Payables & Accruals
- -
- -
- -
ST Debt
507
491
414
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
1.97%
2.83%
Free Cash Flow
- -
-2.81%
-57.56%
Net Income, GAAP
- -
-3%
-144.48%
Sales/Revenue/Turnover
- -
29.12%
38.32%
Total Cash Common Dividend
- -
66.64%
14.89%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
131
172
179
177
658
2025
162
244
- -
236
910
2026
257
286
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.04
-0.06
-0.02
-0.16
-0.28
2025
-0.05
0.12
- -
-0.05
0.13
2026
0.07
0.1
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.01
0.02
0.02
0.07
2025
0.02
0.01
- -
0.02
0.08
2026
0.02
0.07
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Xian Ping Lu
Full Time Employees
1,002
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Zhigu Industrial Park Shenzhen GD China 518057
IPO Date
Aug 12, 2019
Website
chipscreen.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Shenzhen Chipscreen Biosciences Co., Ltd. (688321.SS) engages in the research, development, production, and commercialization of original innovative small-molecule drugs targeting unmet clinical needs in oncology, metabolic diseases, autoimmune disorders, central nervous system disorders, and antivirals; its marketed products include Chidamide (Tucidinostat), an epigenetic modulator approved for peripheral T-cell lymphoma and, as of April 2024, combined with R-CHOP for previously untreated diffuse large B-cell lymphoma with positive MYC and BCL2 expression in China, and Chiglitazar Sodium (Carfloglitazar), a novel insulin sensitizer for type 2 diabetes; the company advances a robust pipeline featuring Chiauranib, a three-way targeted kinase inhibitor (Aurora B, CSF-1R, VEGFR, c-Kit) in phase III for advanced solid tumors, CS23546, a small-molecule PD-L1 dimer antagonist, CS231295, a brain-penetrant Aurora B selective inhibitor, CS32582, a highly selective TYK2 allosteric inhibitor for psoriasis and autoimmune conditions, CS12192, a JAK3 kinase inhibitor, and additional candidates like CS12088 and CS23074. Founded in March 2001 by senior Ph.D. experts returned from the United States and headquartered in Shenzhen, China, the company maintains a global footprint with facilities including a Chengdu regional headquarters and GMP production base, Beijing and Shanghai branches, and a U.S. subsidiary in New Jersey; it leverages an AI-assisted chemical genomics platform for drug discovery and early evaluation. Recent developments encompass expanded approvals for Chidamide in additional lymphoma indications, ongoing phase III trials for Chiauranib, phase II advancement of CS32582 for psoriasis, and a strengthened pipeline layout across five therapeutic areas to address neurodegenerative and other unmet needs, supported by over 700 global patents; the company listed as the first biopharmaceutical firm on China's STAR Market and continues global commercialization of its two marketed drugs across multiple indications in China, Japan, and Taiwan.